A study of Atezolizumab for patients with non-small cell lung cancer (POPLAR)

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

  • Non-Small Cell Lung Cancer
Trial Status:


This trial runs in
  • Albany
  • Antalya
  • Atlanta
  • Austin
  • Avellino
  • Bangkok
  • Basel
  • Billings
  • Binghamton
  • Clermont-Ferrand
  • Detroit
  • Eugene
  • Fairfax
  • Fort Worth
  • Gauting
  • Gdańsk
  • Gyeonggi-do
  • Halle
  • Harvey
  • Hot Springs
  • Immenhausen
  • Istanbul
  • Knoxville
  • La Tronche
  • Las Vegas
  • Laval
  • Leuven
  • Linköping
  • Liège
  • Lodz
  • Loma Linda
  • London
  • Lone Tree
  • Madrid
  • Manchester
  • Milano
  • Montréal
  • Nancy
  • Norfolk
  • Ocala
  • Otwock
  • Paramus
  • Peoria
  • Providence
  • Regensburg
  • Roanoke
  • San Marcos
  • Scarborough
  • Seoul
  • St Brieuc
  • Toulouse
  • Tucson
  • Vallejo
  • Vancouver
  • Walla Walla
  • Warszawa
  • Wenatchee
  • Whittier
  • Zaragoza
Trial Identifier:

NCT01903993 2013-001142-34 GO28753

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter, open-label, randomized study will evaluate the efficacy and safety of Atezolizumab compared with docetaxel in participants with advanced or metastatic non-small cell lung cancer after platinum failure. Participants will be randomized to receive either Atezolizumab 1200 milligram (mg) intravenously every 3 weeks or docetaxel 75 milligram per meter square (mg/m^2) intravenously every 3 weeks. Treatment with Atezolizumab may be continued as long as participants are experiencing clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT01903993 , GO28753 , 2013-001142-34 Trial Identifier
      Docetaxel, Atezolizumab Treatments
      Non-Small Cell Lung Cancer Condition
      Official Title

      A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adult participants, >/= 18 years of age
      • Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)
      • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
      • Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen
      • Measurable disease, as defined by RECIST v1.1
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      Exclusion Criteria
      • Known active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments
      • Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
      • History of autoimmune disease
      • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
      • Active hepatitis B or hepatitis C
      • Prior treatment with docetaxel
      • Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now